BMS fails to appeal NICE no for Orencia
This article was originally published in Scrip
Executive Summary
BMS failed to appeal NICE's earlier decision to not recommend use of Orencia (abatacept) as a second-line treatment for people with rheumatoid arthritis. NICE has now published final guidance not recommending abatacept in combination with methotrexate, for treating RA in adults whose disease has responded inadequately to one or more conventional non-biological disease-modifying anti-rheumatic drugs (DMARDs).